AI Article Synopsis

  • Forgiveness is a key aspect of many religions and offers health and relationship benefits, particularly in lowering stress associated with holding onto negative feelings.
  • This study explored the relationship between forgiveness and immune response (measured by Epstein-Barr virus antibodies) while considering personal factors like relationship value and exploitation risk.
  • Results showed that forgiveness had no notable impact on immune function in low-value relationships, but significantly improved immune health in moderate to high-value relationships, highlighting the importance of the context in which forgiveness occurs.

Article Abstract

Forgiveness is an important component of many of the world's religions that also has benefits for individuals' health and relationships. Research on the health benefits of forgiveness is couched predominately in the stress and coping framework, which views forgiveness as buffering the stress associated with unforgiving feelings. This exploratory study (N = 47) elaborated on the stress and coping framework by investigating it in conversation with an evolutionary approach. Specifically, this study examined one's own forgiveness index (i.e., the interaction of exploitation risk and relationship value) as moderating an association between forgiveness and Epstein-Barr virus (EBV) antibodies. The results indicated that forgiveness shared no significant association with EBV antibodies at low (16th percentile) levels of relationship value (b = - 11, p = .643), but shared an increasingly significant negative association at moderate (50th percentile: b = - 49, p = .038) and high (84th percentile: b = - 84, p = .009) levels, suggesting that forgiveness was more strongly linked to enhanced immune function when occurring in higher valued relationships. Implications for religion, theory, and methodological comparison are discussed.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10943-024-02184-4DOI Listing

Publication Analysis

Top Keywords

exploratory study
8
epstein-barr virus
8
forgiveness
8
stress coping
8
coping framework
8
ebv antibodies
8
study associations
4
associations epstein-barr
4
virus antibodies
4
antibodies forgiveness
4

Similar Publications

The purpose of this study was to evaluate the psychometric properties of the Chinese version of the Revised Indebtedness Scale (IS-R-C) in mainland China. A total of 1057 university students participated in this study using a two-wave whole-group sampling method. Sample 1, consisting of 537 participants, was used for item analysis and exploratory factor analysis (EFA) of the Revised Indebtedness Scale (IS-R).

View Article and Find Full Text PDF

BAY 2413555 is a novel selective and reversible positive allosteric modulator of the type 2 muscarinic acetylcholine (M2) receptor, aimed at enhancing parasympathetic signaling and restoring cardiac autonomic balance for the treatment of heart failure (HF). This study tested the safety, tolerability and pharmacokinetics of this novel therapeutic option. REMOTE-HF was a multicenter, double-blind, randomized, placebo-controlled, phase Ib dose-titration study with two active arms.

View Article and Find Full Text PDF

Structural insights into how Cas9 targets nucleosomes.

Nat Commun

December 2024

Department of Biological Sciences, Graduate School of Science, The University of Tokyo, Tokyo, Japan.

The CRISPR-associated endonuclease Cas9 derived from prokaryotes is used as a genome editing, which targets specific genomic loci by single guide RNAs (sgRNAs). The eukaryotes, the target of genome editing, store their genome DNA in chromatin, in which the nucleosome is a basic unit. Despite previous structural analyses focusing on Cas9 cleaving free DNA, structural insights into Cas9 targeting of DNA within nucleosomes are limited, leading to uncertainties in understanding how Cas9 operates in the eukaryotic genome.

View Article and Find Full Text PDF

Introduction: The efficacy of lipoprotein apheresis (LA) in peripheral arterial disease (PAD) has been primarily attributed to its anti-atherosclerotic effects through the adsorption of lipoproteins. However, the other potential effects of LA remain unknown. We evaluated changes in serum profiles before and after LA using a comprehensive analysis to explore the underlying mechanism.

View Article and Find Full Text PDF

Background: In TALAPRO-2, the poly(ADP-ribose) polymerase inhibitor talazoparib plus the androgen receptor-signaling inhibitor enzalutamide improved radiographic progression-free survival (rPFS) versus placebo plus enzalutamide (hazard ratio [HR] = 0.63; 95% CI, 0.51-0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!